Htay Htay, Cho Yeoungjee, Johnson David W
Department of Renal Medicine, Singapore General Hospital, Singapore.
Centre for Kidney Disease Research, The University of Queensland, Brisbane, QLD, Australia.
Clin Kidney J. 2021 Jan 11;14(3):735-738. doi: 10.1093/ckj/sfaa277. eCollection 2021 Mar.
Relapsing, recurrent or repeat peritonitis is a devastating complication for peritoneal dialysis (PD) patients and is usually associated with poor outcomes including prolonged hospitalization, catheter removal, hemodialysis transfer and even death. Despite its critical importance and frequent occurrence, there is limited available evidence to facilitate evidence-informed treatment of PD peritonitis. This editorial comments on the findings and limitations of a randomized controlled study published in this journal, which reported that extending antibiotic treatment duration for an additional week beyond that recommended by the International Society for PD did not reduce the risk of relapsing, recurrent or repeat peritonitis, and may have increased the risk of repeat peritonitis. These results are explored in the context of the existing literature and recommendations for practice and research are provided.
复发性腹膜炎对腹膜透析(PD)患者而言是一种极具破坏性的并发症,通常与不良预后相关,包括住院时间延长、导管拔除、转为血液透析,甚至死亡。尽管其至关重要且频繁发生,但有助于循证治疗PD腹膜炎的现有证据有限。本社论对发表在本刊的一项随机对照研究的结果和局限性进行了评论,该研究报告称,将抗生素治疗时间比国际腹膜透析学会推荐的时间再延长一周,并不能降低复发性、再发性或反复性腹膜炎的风险,反而可能增加反复性腹膜炎的风险。我们结合现有文献对这些结果进行了探讨,并给出了实践和研究建议。